EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Clinical Performance of OncoPredict HPV Screening Assay on Self‐Collected Vaginal and Urine Specimens Within the VALHUDES Framework

Chiara Giubbi iD, Marianna Martinelli iD, Ardashel Latsuzbaia iD, Kate Cuschieri iD, Hana Elasifer, Anna Daniela Iacobone iD, Fabio Bottari iD, Andrea Fausto Piana, Roberto Pietri, Giancarlo Tisi, Franco Odicino iD, Marc Arbyn iD und 2 weitere

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.70079 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Chiara Giubbi und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. Hauptthemen laut MEDLINE: Papillomavirus Infections, Early Detection of Cancer, Uterine Cervical Neoplasms, Sensitivity and Specificity. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was funded by the Horizon 2020 SME Instrument and Horizon 2020 Framework Programme..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of self‐sampling in cervical cancer screening has raised the importance of HPV test validation on self‐collected samples. This study aimed to evaluate the clinical accuracy of the OncoPredict HPV Screening (SCR) assay on self‐collected vaginal and first‐void urine (FVU) samples, relative to cervical specimens, using the VALHUDES Framework. FVU and vaginal self‐samples followed by a clinician‐collected cervical brushing were collected from 500 women referred to colposcopy and tested using OncoPredict HPV SCR assay. The assay demonstrated clinical sensitivity to detect cervical intraepithelial neoplasia grade 2 or worse (≥ CIN2) similar to cervical samples in FVU (ratio: 0.95, [95% CI: 0.88–1.02]) and vaginal self‐samples (ratio: 0.96 [95% CI: 0.90–1.02]). The clinical specificity for < CIN2 was lower in vaginal (ratio: 0.90 [95% CI: 0.84–0.96]) but not in FVU samples (ratio: 1.03 [95% CI: 0.96–1.12) when compared to cervical samples. However, the relative specificity improved following cut‐off optimization (ratio: 0.94, 95% CI: [0.88–1.01]). Moderate to excellent agreement in HPV detection between self‐collected and cervical samples was demonstrated (Kappa values: 0.53–1.00). To conclude, OncoPredict HPV SCR assay demonstrated similar accuracy on FVU and cervical samples. On vaginal compared to cervical samples sensitivity was similar with a lower specificity, which improved with cut‐off optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsEarly Detection of CancerUterine Cervical NeoplasmsSensitivity and SpecificitySpecimen HandlingUterine Cervical DysplasiaVaginaHumansFemaleAdultMiddle AgedPapillomaviridaeYoung AdultAgedCervix UteriMass ScreeningColposcopyVaginal Smears

Stichwörter der Autor:innen

European VALHUDESHuman PapillomavirusOncoPredict HPV SCRcervical cancerdiagnostic accuracy studyself‐sampling

Autor:innen und Institutionen

  • School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.
  • Scottish HPV Reference Laboratory, Department of Lab Medicine Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
  • HPV Research Group, Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK.
  • Preventive Gynecology Unit, European Institute of Oncology IRCCS, Milan, Italy.
  • General Clinical Laboratory with Specialized Areas Clinical Pathology - Microbiology and Virology, European Institute of Oncology IRCCS, Milan, Italy.

ORCID-Profile: Chiara Giubbi, Marianna Martinelli, Ardashel Latsuzbaia, Kate Cuschieri, Anna Daniela Iacobone, Fabio Bottari, Franco Odicino, Marc Arbyn, Clementina Elvezia Cocuzza

Förderung

  • This research was funded by the Horizon 2020 SME Instrument and Horizon 2020 Framework Programme.

Zitieren

APA

Giubbi, C., Martinelli, M., Latsuzbaia, A., Cuschieri, K., Elasifer, H., Iacobone, A. D., Bottari, F., Piana, A. F., Pietri, R., Tisi, G., Odicino, F., Arbyn, M., Cocuzza, C. E., & European VALHUDES Working Group (2024). Clinical Performance of OncoPredict HPV Screening Assay on Self‐Collected Vaginal and Urine Specimens Within the VALHUDES Framework. Journal of Medical Virology. https://doi.org/10.1002/jmv.70079

Vancouver

Giubbi C, Martinelli M, Latsuzbaia A, Cuschieri K, Elasifer H, Iacobone AD, et al. Clinical Performance of OncoPredict HPV Screening Assay on Self‐Collected Vaginal and Urine Specimens Within the VALHUDES Framework. Journal of Medical Virology. 2024. doi:10.1002/jmv.70079

BibTeX
@article{Giubbi2024,
  author = {Giubbi, Chiara and Martinelli, Marianna and Latsuzbaia, Ardashel and Cuschieri, Kate and Elasifer, Hana and Iacobone, Anna Daniela and Bottari, Fabio and Piana, Andrea Fausto and Pietri, Roberto and Tisi, Giancarlo and Odicino, Franco and Arbyn, Marc and Cocuzza, Clementina Elvezia and European VALHUDES Working Group, European VALHUDES Working Group},
  title = {Clinical Performance of OncoPredict HPV Screening Assay on Self‐Collected Vaginal and Urine Specimens Within the VALHUDES Framework},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.70079}
}
Kostenlos starten →